Ligand Pharmaceuticals Incorporated (LGND) Q1 2019 Earnings Results

Ligand Pharmaceuticals Misses on EPS, Stock Up 1.1%

The earnings report shows that Ligand Pharmaceuticals had a significant miss on EPS, which could raise concerns among investors about the company's financial health. Despite this, the stock reacted positively, increasing by 1.1%. This may indicate that investors are looking past the EPS miss, possibly due to other factors not disclosed in the earnings report.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$1.16	N/A	-90.55%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management expressed concern over the EPS results, indicating challenges in meeting expectations. They did not provide any forward guidance, leaving investors uncertain about future performance.

Management acknowledged the significant EPS miss compared to expectations.

No specific guidance was provided for future quarters.

Ligand Pharmaceuticals Misses on EPS, Stock Up 1.1%

Key numbers

Management commentary

Ligand Pharmaceuticals Incorporated

More earnings this week

Ligand Pharmaceuticals Misses on EPS, Stock Up 1.1%

Key numbers

Management commentary